Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411671 · ClinicalTrials.gov registry record · Phase 2
BATTLE Program: Sorafenib in Patients With NSCLC
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00411671: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00411671 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00411671, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
Primary Objective: * To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen. Secondary Objective: The secondary objectives of this study will be to: * Determine the overall response rate * Determine the overall survival * Determine the time to disease progression * Assess the safety/toxicity of the study treatment * Assess biomarker modulation in the tumor tissue and serum samples from the treatment. * Assess plasma and intra-tumor concentrations of study treatment
Interventions
- DRUG Sorafenib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411671
The ClinicalTrials.gov registry entry for NCT00411671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib is the first listed.
NCT00411671 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00411671 about?
NCT00411671 is a clinical study titled "BATTLE Program: Sorafenib in Patients With NSCLC". Primary Objective: * To determine the 8 week progression-free survival rate (i.e. disease control rate) in patients with advanced non-small cell lung cancer (NSCLC) who have failed at least one prior chemotherapy regimen. Secondary Objective: The secondary objectives of this study will be to: * ...
What is the current status of trial NCT00411671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2006-11. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00411671?
The interventions under investigation include: Sorafenib (DRUG).
Who is sponsoring clinical trial NCT00411671?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.